Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.

Mostrar outras versões (1)

PURPOSE: We investigated the value of serum measurements for glandular kallikrein 2 (hK2), and free (f) and total (t) prostate specific antigen (PSA) in a second round of biannual screening for prostate cancer. MATERIALS AND METHODS: In 1995 to 1996, 5,853 of 9,811 randomly selected men in Göteborg...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Becker, C, Piironen, T, Pettersson, K, Hugosson, J, Lilja, H
Formato:	Journal article
Idioma:	English
Publicado em:	2003

Registros relacionados

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
por: Becker, C, et al.
Publicado em: (2003)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
por: Becker, C, et al.
Publicado em: (2000)

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.
por: Becker, C, et al.
Publicado em: (2000)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
por: Steuber, T, et al.
Publicado em: (2005)

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
por: Becker, C, et al.
Publicado em: (2000)

Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen.
por: Olsson, A, et al.
Publicado em: (2004)

Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
por: Ylikoski, A, et al.
Publicado em: (2001)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
por: Siivola, P, et al.
Publicado em: (2000)

Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
por: Väisänen, V, et al.
Publicado em: (2006)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
por: Steuber, T, et al.
Publicado em: (2007)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
por: Haese, A, et al.
Publicado em: (2001)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
por: Hugosson, J, et al.
Publicado em: (2003)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
por: Cao, Y, et al.
Publicado em: (2002)

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
por: Ylikoski, A, et al.
Publicado em: (2002)

Development of sensitive immunoassays for free and total human glandular kallikrein 2.
por: Väisänen, V, et al.
Publicado em: (2004)

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
por: Nurmikko, P, et al.
Publicado em: (2001)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
por: Becker, C, et al.
Publicado em: (2001)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
por: Aus, G, et al.
Publicado em: (2004)

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
por: Ulmert, D, et al.
Publicado em: (2006)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
por: Olsson, A, et al.
Publicado em: (2005)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
por: Steuber, T, et al.
Publicado em: (2006)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
por: Haese, A, et al.
Publicado em: (2003)

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
por: Aus, G, et al.
Publicado em: (2003)

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
por: Haese, A, et al.
Publicado em: (2005)

Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
por: Björk, T, et al.
Publicado em: (2001)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
por: Vickers, A, et al.
Publicado em: (2008)

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
por: Haese, A, et al.
Publicado em: (2000)

Total and gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
por: Haese, A, et al.
Publicado em: (2003)

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
por: Haese, A, et al.
Publicado em: (2003)

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
por: Hugosson, J, et al.
Publicado em: (2004)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
por: Vickers, A, et al.
Publicado em: (2010)

Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
por: Bruun, L, et al.
Publicado em: (2004)

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
por: Bruun, L, et al.
Publicado em: (2005)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
por: Törnblom, M, et al.
Publicado em: (2001)

Standardization of two immunoassays for human glandular kallikrein 2.
por: Haese, A, et al.
Publicado em: (2003)

Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
por: Janssen, S, et al.
Publicado em: (2004)

Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection.
por: Zackrisson, B, et al.
Publicado em: (2003)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
por: Zackrisson, B, et al.
Publicado em: (2003)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
por: Wenske, S, et al.
Publicado em: (2009)

[Isoforms of free prostate-specific antigen]
por: Haese, A, et al.
Publicado em: (2004)